Why is Stoke Therapeutics stock gaining today?

Stoke Therapeutics stock experienced a 1.4% increase in pre-market trading on August 19, 2025, following JPMorgan's initiation of coverage with an Overweight rating and a $40 price target. This endorsement adds to the growing consensus among Wall Street analysts, with a total of 14 buy-side analysts now covering the Bedford, Massachusetts-based biotechnology company.

Notably, there are no hold or sell ratings on record, indicating near-unanimous institutional confidence in the company's growth prospects. JPMorgan's assessment aligns with previous recommendations from Goldman Sachs, who gave the stock a Buy rating and a $44 price target, and Guggenheim, who maintained a Buy stance with a $60 price target.

Additionally, Wedbush upgraded its rating to Outperform with a $40 price target following the company's second-quarter results. Stoke Therapeutics also announced on August 18 that it had granted inducement stock options to seven newly hired employees, signaling active team expansion as the company moves towards a potential commercial launch.

The Phase 3 EMPEROR study, evaluating zorevunersen as a disease-modifying treatment for Dravet syndrome, recently completed patient enrollment with 162 participants. The company remains confident in its cash runway, projecting operations through early 2028. The broader market contributed to the positive sentiment, with the S&P 500, Dow Jones, and Nasdaq all up by 0.3%, 0.4%, and 0.5%, respectively, in pre-market trading.

As a result, Stoke Therapeutics' stock is trading at $31.85, still approximately 21% below its 52-week high of $40.22, suggesting potential for further upside if clinical milestones are met.